본문 바로가기

Impact of alemtuzumab as conditioning regimen component on transplantation outcomes in case of CMV-seropositive recipients and donors

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q3
저널
AMERICAN JOURNAL OF HEMATOLOGY83(8) · pp.649 · 2008
피인용
Web of Science 13
JCR IF
JCR 2007 1.949
ISSN
0361-8609

저자

  1. Yee, Soo Chae제1저자Department of Hematology/Oncology, Kyungpook National University Hospital, South Korea
  2. Sang, Kyun Sohn교신저자Department of Hematology/Oncology, Kyungpook National University Hospital, South Korea
  3. Jong, Gwang KimDepartment of Hematology/Oncology, Kyungpook National University Hospital, South Korea
  4. Yoon, Young ChoDepartment of Hematology/Oncology, Kyungpook National University Hospital, South Korea
  5. Joon, Ho MoonDepartment of Hematology/Oncology, Kyungpook National University Hospital, South Korea
  6. Deok, Hwan YangDepartment of Hematology/Oncology, Chonnam National University Hospital, South Korea
  7. Lee, Je-JungDepartment of Hematology/Oncology, Chonnam National University Hospital, South Korea
  8. Kim, Yeo-KyeoungDepartment of Hematology/Oncology, Chonnam National University Hospital, South Korea
  9. Kim, Hyeoung-JoonDepartment of Hematology/Oncology, Chonnam National University Hospital, South Korea
  10. 신호진Department of Hematology/Oncology, Pusan National University Hospital, South Korea
  11. 정주섭Department of Hematology/Oncology, Pusan National University Hospital, South Korea
  12. 조군제Department of Hematology/Oncology, Pusan National University Hospital, South Korea

초록

We studied the incidence of cytomegalovirus (CMV) infection, clinical outcomes, and complications in 39 recipients of alemtuzumab-containing conditioning-stem cell transplantation, who were classified into two groups based on the median dose (35 mg) of alemtuzumab. All the recipients and donors were CMV-seropositive before transplantation. The median survival duration was 321 days (range, 46-1098 days) and the 2-year survival rate was 47.8%. The probability of nonrelapse mortality at 100 days and 2 years was 14.6% and 31.2%, respectively. The cumulative incidence of Grade II-IV acute graft-versus-host disease (GVHD) at Day 100 was 21.8%. The overall incidence of chronic GVHD (cGVHD) was 28.6%, including a 17.9% incidence of extensive cGVHD. The cumulative incidence of CMV antigenemia was 68.0%. There were no statistical differences in the engraftment, acute and cGVHD, relapse, CIVIV antigenemia, and overall survival (OS) between the two groups. Yet, the nonrelapse mortality (NRM) was significantly lower for the low-dose group (5.9% vs. 51.7%, P = 0.010). The present study showed that alemtuzumab was effective for GVHD prevention, yet caused a relatively high incidence of CIVIV antigenemia, regardless of the dose. Thus, a low dose of alemtuzumab (! 35 mg) would seem to be preferable in an allogeneic SCT setting when both the recipient and the donor are CIVIV seropositive.

식별자

WoS UID
000258250900010